Abstract:OBJECTIVE:To investigate the impact of early rapid virological response on the outcomes of hepatitis B associated acute on chronic liver failure during antiviral treatment.METHODS:106 acute on chronic liver failure patients in our hospital from January 2008 to July 2010 were enrolled in present study retrospectively. Besides internal medicine therapy, all patients received lamivudine (100 mg/d) or entecavir (0.5 mg/d) treatment. The profile of liver biochemistry, prothrombin time activity and viral load were detected at baseline and week 4, respectively. The patients were divided into HBV DNA negative group and HBV DNA positive group according to the viral load at week 4. The clinical features and treatment outcomes were compared between groups. Frequency variables were compared by x2 test or Fisher's exact test. Continuous variables were compared using independent samples T-test. The factors that impact on the treatment outcomes were determined using stepwise multivariate logistic regression analysis.RESULTS:At the week 4, the TBil and PTA in HBV DNA positive group [(261.6+/-205.6)mumol/L and 44.7%+/-19.7%, respectively] were significantly different from those in HBV DNA negative group [(160.1+/-173.4) mumol/L and 56.8%+/-23.1%, respectively] ( t = 2.190 and -2.077, respectively, P less than 0.05). The non-effective rate of HBVDNA positive group (50%, 9/18) was significantly higher than that of HBV DNA negative group (14.8%, 13/88) (x2 = 9.235, P less than 0.01). By using stepwise multivariate logistic regression analysis, the disease stage and HBV DNA undetectable at week 4 were the independent factor. The OR values of disease stage and HBV DNA undetectable were 6.559 and 0.209, respectively, and 95% CI was 2.316~18.576 and 0.058~0.747, respectively.CONCLUSION:The rapid suppression of viral load by nucleotide analogue may improve the efficacy of hepatitis B associated acute on chronic liver failure treatment. The early rapid virological response within first 4 weeks may contribute to the prediction of the treatment outcomes.

Study on Preparation of Acyclovir Liposomes and Its Role in Inhibiting Hepatitics B in Vitro

High yield synthesis,structure confirm of acyclovir palmitate and its role in inhibiting hepatitics B in vitro

Biologic Activity Estimation of Anti-hepatitis B Immune RNA Wrapped in Liposome in Mice

[Preparation of Nosiheptide Liposomes and Its Inhibitory Effect on Hepatitics B Virus in Vitro].

The Impact of Early Rapid Virological Response on the Outcomes of Hepatitis B Associated Acute on Chronic Liver Failure During Antiviral Treatment

Liver Targeting and Anti-Hbv Activity of Reconstituted HDL–acyclovir Palmitate Complex

Synthesis and Anti-Hepatitis B Virus Activity of Acyclovir Conjugated Stearic Acid-G-chitosan Oligosaccharide Micelle

Repurposing of Antazoline Hydrochloride as an Inhibitor of Hepatitis B Virus DNA Secretion

Study on the Relation of Glycyrrhizic Glycoside on Hepatitis B Virus Replication in Vitro

INHIBITION OF HEPATITIS B VIRUS BY COMBINED Sirnas IN VITRO

[Efficacy of antiviral treatment on intrahepatic HBV DNA and histology in HBeAg -positive chronic hepatitis B patients].

Intrahepatic HBV DNA As a Predictor of Antivirus Treatment Efficacy in HBeAg-positive Chronic Hepatitis B Patients.

Antiviral Effect of Adefovir Dipivoxil Loaded Solid Lipid Nanoparticles in Vitro

A Study on the Clinical and Pathological Efficacy of Lamivudine in the Treatment of Chronic Hepatitis B

In Vitro Inhibition of HBV Replication by a Novel Compound, GLS4, and Its Efficacy Against Adefovir-Dipivoxil-resistant HBV Mutations

[Cationic liposomes enhance the inhibitory effects of antisense oligodeoxynucleotide on hepatitis B virus].

[Transfection and Anti-Hbv Effect Mediated by the Hepatocytes-Targeting Cationic Liposomes Co-Modified with Beta-Sitosterol-beta-d-glucoside and Brij 35].

In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates

Inhibition of Hepatitis B Virus Replication by Bay 41-4109 and Its Association with Nucleocapsid Disassembly.

Hepatocyte-targeting and Microenvironmentally Responsive Glycolipid-Like Polymer Micelles for Gene Therapy of Hepatitis B.

Role of Intrahepatic HBV DNA in Antivirus Therapy